Atrial Fibrillation Surgery Market Players:
- Abbott Laboratories.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- AtriCure, Inc.,
- Biosense Webster, Inc.,
- Boehringer Ingelheim GmbH
- Boston Scientific Corporation
- Bristol-Myers Squibb Corporation
- CardioFocus, Inc.,
- Endoscopic Technologies, Inc.,
- Sanofi Aventis,
- Johnson and Johnson Ltd.,
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of the atrial fibrillation surgery was over USD 5.21 billion.
The global atrial fibrillation surgery sector registered a profitable valuation of USD 5.21 billion in 2026 and is poised to reach USD 18.65 billion by 2036, expanding at a CAGR of 13.6% during the forecast period, i.e., 2027-2036.
The North America atrial fibrillation surgery market is expected to hold a 32% share by 2036, driven by technological advancements, increasing prevalence of cardiac conditions, and favorable insurance coverage.
Key players in the market include Abbott Laboratories., AtriCure, Inc., Biosense Webster, Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Endoscopic Technologies, Inc., Sanofi Aventis, Johnson and Johnson Ltd.
